India MCA Insolvency Liquidation Filings — June 25, 2026

NCLAT stay on insolvency after full settlement of ₹91.99 lakhs claim; market cap of ~₹9,000 Cr saved from immediate distress; next hearing on June 29, 2026

CIRP advancing with 9 eligible PRAs; deadline for document submission June 27, 2026; potential for a resolution plan that could unlock value for creditors

Promoter reclassification approved after 15-month delay; 9 erstwhile promoters moved to 'Public' category, cleaning up shareholding structure post-resolution plan

NCLT approves amalgamation with QCIL; record date July 9, 2026; share exchange ratio of 977:1,000 indicates a premium for QCIL shareholders

44th CoC meeting scheduled; company under CIRP since 2019 with no resolution plan yet; prolonged process signals deep distress and limited recovery prospects

Operational creditor claim fully settled; company argued insolvency would harm financial reputation; this sets a precedent for other companies facing small creditor claims

Two applicants rejected (Ambica Cotseeds for net-worth, Globaledge/Standard Capital for EMD); indicates strict adherence to IBC norms and quality screening of PRAs

Scheme of Amalgamation with QCIL will result in share issuance; no financial details disclosed but the deal structure suggests strategic consolidation in healthcare

Company under CIRP since August 2019 (7+ years); 44th CoC meeting with no resolution plan disclosed; risk of liquidation if no viable plan emerges

Stay is temporary until June 29, 2026; if NCLAT reverses, insolvency proceedings resume, threatening operations of a ₹4,800 Cr revenue company

Two out of 11 applicants rejected; if remaining 9 fail to submit viable plans, the CIRP could stall, leading to liquidation

One erstwhile promoter (Sandepudi Hanumantha Rao) died in 2022; legal complexities around share transfer and succession could arise

Filing provides no financial results or progress update; lack of transparency increases uncertainty for creditors and investors

Insolvency was triggered by a relatively small claim (₹91.99 lakhs) from Isitva Steel; suggests potential working capital or payment disputes

Globaledge Dynamics and Standard Capital Market rejected for non-receipt of EMD; indicates procedural lapses or lack of serious intent

Issuance of 977 shares per 1,000 QCIL shares will dilute existing Aster shareholders; no financial impact disclosed yet

Opportunity for distressed debt investors to acquire operational creditor claims at a discount; company's strong fundamentals (₹9,000 Cr mcap, ₹4,800 Cr revenue) suggest recovery potential

9 eligible PRAs with June 27 deadline; if a resolution plan is approved, equity holders could see value recovery; monitor for plan details

Record date July 9, 2026 for QCIL shareholders; arbitrage opportunity between QCIL shares and Aster shares based on exchange ratio

Promoter reclassification completed; company now has a clean shareholding structure, potentially attracting institutional investors

Despite prolonged CIRP, HDIL holds prime real estate assets in Mumbai; a resolution plan could unlock significant value for creditors

The full settlement of a small operational creditor claim sets a precedent; other companies facing similar claims may settle quickly to avoid insolvency

Company operates in IT infrastructure; sector tailwinds could attract strategic buyers for the distressed asset

Amalgamation with QCIL creates a larger healthcare entity; potential synergies and cost savings could boost profitability

HDIL's 7+ year CIRP highlights the chronic delays in resolving real estate insolvencies, often due to complex asset structures and multiple stakeholders

Vikram Solar's case shows how relatively small operational creditor claims (₹91.99 lakhs) can threaten large-cap companies, emphasizing the need for robust working capital management

PS IT Infrastructure's rejection of two applicants for net-worth and EMD non-compliance demonstrates increasing regulatory rigor in the CIRP process

Neueon Corporation's promoter reclassification post-resolution plan shows that successful IBC outcomes can lead to corporate governance improvements and potential value unlocking

Aster DM-QCIL amalgamation under NCLT approval reflects a broader trend of consolidation in Indian healthcare, creating larger entities with better market positioning

Neueon's 15-month wait for promoter reclassification approval highlights the slow pace of regulatory processes, which can delay value realization for investors

Next hearing on June 29, 2026; outcome will determine if insolvency proceedings resume or are permanently stayed; critical for company's future

Deadline June 27, 2026 for PRAs to submit pending documents; watch for any further rejections or progress on resolution plans

Meeting on June 25, 2026; any announcement of a resolution plan or liquidation decision will be material for creditors

July 9, 2026 record date for QCIL shareholders; watch for share price movements and any regulatory approvals pending

Post-reclassification, monitor for any changes in shareholding or insider transactions as the company transitions to public category

Monitor if Isitva Steel Private Limited has any further claims or if the settlement leads to other creditors stepping forward

After June 27, watch for submission of resolution plans and CoC evaluation; potential catalyst for stock if plan is favorable

Watch for any shareholder dissent or legal challenges to the amalgamation scheme before the record date